Skip to content

The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine

A Randomized Double Blind, Placebo Controlled Phase III Trial to Determine the Efficacy and Safety of Topical Intra-oral Ketoprofen for the Treatment of Acute Migraine

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01228552
Enrollment
100
Registered
2010-10-26
Start date
2011-12-31
Completion date
2012-01-31
Last updated
2011-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Migraine, Migraine, Migraine Disorders, Migraine Headache

Keywords

Acute Migraine Treatment, Migraine Treatment, Migraine, Headache, Treatment

Brief summary

The purpose of this study is to evaluate the efficacy and safety of intra-oral topical ketoprofen for the treatment of acute migraine.

Interventions

DRUGTopical, intra-oral ketoprofen gel

Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.

OTHERPlacebo gel

Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.

Sponsors

Behar, Caren, M.D.
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Established diagnosis of Migraine as per IHS with aura * Established diagnosis of Migraine as per IHS without aura * At least 2 migraines per month * At least 18 years of age

Exclusion criteria

* Pregnancy or Lactation * Other Headache Conditions including basilar, hemiplegic, or ophthalmoplegic migraines * Chronic Daily Headache * Allergy or Sensitivity to NSAIDs * Other Severe Medical Conditions including GI bleeding, blood dyscrasias, thrombocytopenia

Design outcomes

Primary

MeasureTime frame
Pain relief (defined as at least 2 graded reduction in a 5-grade scale) at 120 minutes post-treatmentWithin 240 minutes post-treatment

Secondary

MeasureTime frame
Pain relief at 30, 60, and 240 minutes post-treatment based on headache severities reported in patient's journalsWithin 240 minutes post-treatment
Relief of Photophobia at 30, 60, 120, and 240 minutes post-treatmentWithin 240 minutes post-treatment
Relief of Phonophobia at 30, 60, 120, and 240 minutes post-treatmentWithin 240 minutes post-treatment
Pain free status at 30, 60, 120, and 240 minutes post-treatment based on headache severities reported in patient's journalsWithin 240 minutes post-treatment
Relief of Vomiting 30, 60, 120 and 240 minutes post-treatmentWithin 240 minutes post-treatment
Need for Rescue Medication between the time of dosing to 240 minutesWithin 240 minutes post-treatment
Relief of Nausea at 30, 60, 120 and 240 minutes post-treatmentWithin 240 minutes post-treatment

Countries

United States

Contacts

Primary ContactCaren Behar, MD
ardavsa@aol.com914-584-2413

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026